(via NewsDirect)
Barder says that despite losses, revenues "are now rapidly coming over the horizon" and he suggests "the last two years have been very very good for us".
He adds that he's "confident of getting FDA approval for MED3000 this quarter"
Contact Details
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source